LIN28A modulates splicing and gene expression programs in breast cancer cells

Molecular and Cellular Biology

Volumn 35, Issue 18, 2015, Pages 3225-3243

  Yang, Jun ^a   Bennett, Brian D ^a   Luo, Shujun ^b,c   Inoue, Kaoru ^a   Grimm, Sara A ^a   Schroth, Gary P ^b   Bushel, Pierre R ^a   Kinyamu, H Karimi ^a   Archer, Trevor K ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b ILLUMINA INC   (United States)

^c Personalis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; LIN28A PROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ENAH PROTEIN, HUMAN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN GROUP A B; HNRNP A1; ISOPROTEIN; LIN28B PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; EMBRYO; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA METABOLISM; RNA SPLICING; TRANSLATION INITIATION; ALTERNATIVE RNA SPLICING; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; DNA SEQUENCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LONG TERMINAL REPEAT; MCF-7 CELL LINE; METABOLISM; MOUSE MAMMARY TUMOR VIRUS; NUCLEOTIDE SEQUENCE; PROMOTER REGION; RNA INTERFERENCE; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; MAMMARY TUMOR VIRUS, MOUSE; MCF-7 CELLS; MICROFILAMENT PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; TERMINAL REPEAT SEQUENCES;

EID: 84939639034     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00426-15     Document Type: Article

References (62)

1. Shyh-Chang N, Daley GQ. 2013. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell 12:395-406. http://dx.doi.org/10.1016/j.stem.2013.03.005.
2. Thornton JE, Gregory RI. 2012. How does Lin28 let-7 control development and disease? Trends Cell Biol 22:474-482. http://dx.doi.org/10.1016/j.tcb.2012.06.001.
3. Ambros V, Horvitz HR. 1984. Heterochronic mutants of the nematode Caenorhabditis elegans. Science 226:409-416. http://dx.doi.org/10.1126/science.6494891.
4. Moss EG, Tang L. 2003. Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites. Dev Biol 258:432-442. http://dx.doi.org/10.1016/S0012-1606(03)00126-X.
5. Peng S, Chen LL, Lei XX, Yang L, Lin H, Carmichael GG, Huang Y. 2011. Genome-wide studies reveal that Lin28 enhances the translation of genes important for growth and survival of human embryonic stem cells. Stem Cells 29:496-504. http://dx.doi.org/10.1002/stem.591.
6. Richards M, Tan SP, Tan JH, Chan WK, Bongso A. 2004. The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 22:51-64. http://dx.doi.org/10.1634/stemcells.22-1-51.
7. Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H. 2009. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer 45:2212-2218. http://dx.doi.org/10.1016/j.ejca.2009.05.003.
8. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. 2009. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41:843-848. http://dx.doi.org/10.1038/ng.392.
9. Yang DH, Moss EG. 2003. Temporally regulated expression of Lin-28 in diverse tissues of the developing mouse. Gene Expr Patterns 3:719-726. http://dx.doi.org/10.1016/S1567-133X(03)00140-6.
10. Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR, Takeuchi A, Grasemann C, Rinn JL, Lopez MF, Hirschhorn JN, Palmert MR, Daley GQ. 2010. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet 42:626-630. http://dx.doi.org/10.1038/ng.593.
11. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR. 2009. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 28:347-358. http://dx.doi.org/10.1038/emboj.2008.294.
12. Newman MA, Thomson JM, Hammond SM. 2008. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA 14:1539-1549. http://dx.doi.org/10.1261/rna.1155108.
13. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wulczyn FG. 2008. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol 10:987-993. http://dx.doi.org/10.1038/ncb1759.
14. Viswanathan SR, Daley GQ, Gregory RI. 2008. Selective blockade of microRNA processing by Lin28. Science 320:97-100. http://dx.doi.org/10.1126/science.1154040.
15. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635-647. http://dx.doi.org/10.1016/j.cell.2005.01.014.
16. Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315:1576-1579. http://dx.doi.org/10.1126/science.1137999.
17. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Krueger LJ. 2007. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67:9762-9770. http://dx.doi.org/10.1158/0008-5472.CAN-07-2462.
18. Xia Y, Zhu Y, Zhou X, Chen Y. 2014. Low expression of let-7 predicts poor prognosis in patients with multiple cancers: a meta-analysis. Tumour Biol 35:5143-5148. http://dx.doi.org/10.1007/s13277-014-1663-0.
19. Balzer E, Heine C, Jiang Q, Lee VM, Moss EG. 2010. LIN28 alters cell fate succession and acts independently of the let-7 microRNA during neurogliogenesis in vitro. Development 137:891-900. http://dx.doi.org/10.1242/dev.042895.
20. Cho J, Chang H, Kwon SC, Kim B, Kim Y, Choe J, Ha M, Kim YK, Kim VN. 2012. LIN28A is a suppressor of ER-associated translation in embryonic stem cells. Cell 151:765-777. http://dx.doi.org/10.1016/j.cell.2012.10.019.
21. Polesskaya A, Cuvellier S, Naguibneva I, Duquet A, Moss EG, Harel-Bellan A. 2007. Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. Genes Dev 21:1125-1138. http://dx.doi.org/10.1101/gad.415007.
22. Xu B, Zhang K, Huang Y. 2009. Lin28 modulates cell growth and associates with a subset of cell cycle regulator mRNAs in mouse embryonic stem cells. RNA 15:357-361. http://dx.doi.org/10.1261/rna.1368009.
23. Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, Urbach A, Thornton JE, Triboulet R, Gregory RI, Altshuler D, Daley GQ. 2011. The Lin28/ let-7 axis regulates glucose metabolism. Cell 147:81-94. http://dx.doi.org/10.1016/j.cell.2011.08.033.
24. Hafner M, Max KE, Bandaru P, Morozov P, Gerstberger S, Brown M, Molina H, Tuschl T. 2013. Identification of mRNAs bound and regulated by human LIN28 proteins and molecular requirements for RNA recognition. RNA 19:613-626. http://dx.doi.org/10.1261/rna.036491.112.
25. Li N, Zhong X, Lin X, Guo J, Zou L, Tanyi JL, Shao Z, Liang S, Wang LP, Hwang WT, Katsaros D, Montone K, Zhao X, Zhang L. 2012. Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer. J Biol Chem 287:17386-17397. http://dx.doi.org/10.1074/jbc.M111.321158.
26. Wilbert ML, Huelga SC, Kapeli K, Stark TJ, Liang TY, Chen SX, Yan BY, Nathanson JL, Hutt KR, Lovci MT, Kazan H, Vu AQ, Massirer KB, Morris Q, Hoon S, Yeo GW. 2012. LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance. Mol Cell 48:195-206. http://dx.doi.org/10.1016/j.molcel.2012.08.004.
27. Warburg O. 1956. On the origin of cancer cells. Science 123:309-314. http://dx.doi.org/10.1126/science.123.3191.309.
28. Feng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y. 2012. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 11:2486-2494. http://dx.doi.org/10.4161/cc.20893.
29. Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y, Dong M, Teng R, Wu L, Fu P, Deng W, Hu W, Teng L. 2012. Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells. PLoS One 7:e40008. http://dx.doi.org/10.1371/journal.pone.0040008.
30. Keene JD, Komisarow JM, Friedersdorf MB. 2006. RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. Nat Protoc 1:302-307. http://dx.doi.org/10.1038/nprot.2006.47.
31. Williams JG, Tomer KB, Hioe CE, Zolla-Pazner S, Norris PJ. 2006. The antigenic determinants on HIV p24 for CD4 T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry. J Am Soc Mass Spectrom 17:1560-1569. http://dx.doi.org/10.1016/j.jasms.2006.06.011.
32. Kinyamu HK, Archer TK. 2003. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol Cell Biol 23:5867-5881. http://dx.doi.org/10.1128/MCB.23.16.5867-5881.2003.
33. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10:R25. http://dx.doi.org/10.1186/gb-2009-10-3-r25.
34. Fryer CJ, Archer TK. 1998. Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 393:88-91. http://dx.doi.org/10.1038/30032.
35. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70. http://dx.doi.org/10.1038/nature11412.
36. Kinyamu HK, Collins JB, Grissom SF, Hebbar PB, Archer TK. 2008. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition. Mol Carcinog 47:845-885. http://dx.doi.org/10.1002/mc.20440.
37. Darr H, Benvenisty N. 2009. Genetic analysis of the role of the reprogramming gene LIN-28 in human embryonic stem cells. Stem Cells 27:352-362. http://dx.doi.org/10.1634/stemcells.2008-0720.
38. Tan SM, Altschuler G, Zhao TY, Ang HS, Yang H, Lim B, Vardy L, Hide W, Thomson AM, Lareu RR. 2014. Divergent LIN28-mRNA associations result in translational suppression upon the initiation of differentiation. Nucleic Acids Res 42:7997-8007. http://dx.doi.org/10.1093/nar/gku430.
39. Jean-Philippe J, Paz S, Caputi M. 2013. hnRNP A1: the Swiss army knife of gene expression. Int J Mol Sci 14:18999-19024. http://dx.doi.org/10.3390/ijms140918999.
40. Chen M, David CJ, Manley JL. 2012. Concentration-dependent control of pyruvate kinaseMmutually exclusive splicing by hnRNP proteins. Nat Struct Mol Biol 19:346-354. http://dx.doi.org/10.1038/nsmb.2219.
41. Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. 2010. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A 107:1894-1899. http://dx.doi.org/10.1073/pnas.0914845107.
42. David CJ, Chen M, Assanah M, Canoll P, Manley JL. 2010. hnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364-368. http://dx.doi.org/10.1038/nature08697.
43. Huelga SC, Vu AQ, Arnold JD, Liang TY, Liu PP, Yan BY, Donohue JP, Shiue L, Hoon S, Brenner S, Ares M, Jr, Yeo GW. 2012. Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Rep 1:167-178. http://dx.doi.org/10.1016/j.celrep.2012.02.001.
44. Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perracchio L, Venturo I, Botti C, Jager E, Santoni A, Natali PG, Nistico P. 2006. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor- negative tumors. Clin Cancer Res 12:1470-1478. http://dx.doi.org/10.1158/1078-0432.CCR-05-2027.
45. Du JW, Xu KY, Fang LY, Qi XL. 2012. Clinical significance of Mena and Her-2 expression in breast cancer. Eur J Gynaecol Oncol 33:455-458.
46. Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D, Gregory RI. 2011. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147:1066-1079. http://dx.doi.org/10.1016/j.cell.2011.10.039.
47. Ward PS, Thompson CB. 2012. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308. http://dx.doi.org/10.1016/j.ccr.2012.02.014.
48. Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA. 2011. Interactions with fibroblasts are distinct in basal-like and luminal breast cancers. Mol Cancer Res 9:3-13. http://dx.doi.org/10.1158/1541-7786.MCR-10-0372.
49. Gerson SL. 2004. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307. http://dx.doi.org/10.1038/nrc1319.
50. Liu CT, Buchkovich ML, Winkler TW, Heid IM, African Ancestry Anthropometry Genetics Consortium, GIANT Consortium, Borecki IB, Fox CS, Mohlke KL, North KE, Adrienne Cupples L. 2014. Multi-ethnic fine-mapping of 14 central adiposity loci.HumMol Genet 23:4738-4744. http://dx.doi.org/10.1093/hmg/ddu183.
51. Qattan AT, Mulvey C, Crawford M, Natale DA, Godovac-Zimmermann J. 2010. Quantitative organelle proteomics of MCF-7 breast cancer cells reveals multiple subcellular locations for proteins in cellular functional processes. J Proteome Res 9:495-508. http://dx.doi.org/10.1021/pr9008332.
52. Caceres JF, Stamm S, Helfman DM, Krainer AR. 1994. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science 265:1706-1709. http://dx.doi.org/10.1126/science.8085156.
53. Mayeda A, Krainer AR. 1992. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 68:365-375. http://dx.doi.org/10.1016/0092-8674(92)90477-T.
54. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. 2013. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155:397-409. http://dx.doi.org/10.1016/j.cell.2013.09.025.
55. Di Modugno F, DeMonte L, Balsamo M, Bronzi G, Nicotra MR, Alessio M, Jager E, Condeelis JS, Santoni A, Natali PG, Nistico P. 2007. Molecular cloning of hMena (ENAH) and its splice variant hMena 11a:epidermal growth factor increases their expression and stimulates hMena 11a phosphorylation in breast cancer cell lines. Cancer Res 67:2657-2665. http://dx.doi.org/10.1158/0008-5472.CAN-06-1997.
56. Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L, Carstens RP, Santoni A, Bissell MJ, Nistico P. 2012. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci U S A 109:19280-19285. http://dx.doi.org/10.1073/pnas.1214394109.
57. Carpenter S, Ricci EP, Mercier BC, Moore MJ, Fitzgerald KA. 2014. Post-transcriptional regulation of gene expression in innate immunity. Nat Rev Immunol 14:361-376. http://dx.doi.org/10.1038/nri3682.
58. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706. http://dx.doi.org/10.1016/j.cell.2009.10.014.
59. David CJ, Manley JL. 2010. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24:2343-2364. http://dx.doi.org/10.1101/gad.1973010.
60. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB. 2011. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7:e1002218. http://dx.doi.org/10.1371/journal.pgen.1002218.
61. Di Modugno F, Mottolese M, DeMonte L, Trono P, Balsamo M, Conidi A, Melucci E, Terrenato I, Belleudi F, Torrisi MR, Alessio M, Santoni A, Nistico P. 2010. The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS One 5:e15852. http://dx.doi.org/10.1371/journal.pone.0015852.
62. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646-674. http://dx.doi.org/10.1016/j.cell.2011.02.013.